D-Wave Quantum: A $100 Million CHIPS Lifeline, a 611% Bookings Surge and the Quarterly Dip That Tests the Story

D-Wave Quantum has handed investors a puzzle with two very different pieces. One is a conditional pathway to as much as $100 million under the CHIPS and Science Act, contingent on hitting specified milestones and conditions. The other is a set of Tuesday results that show explosive order growth over nine months alongside a quarterly bookings retreat and a wider loss. The stock slipped 2.8% on Friday to close at €8.66, having already given ground after the earnings release.

The funding arrangement is the headline that draws the eye, but it is a framework rather than a windfall. It can widen D-Wave's financial room to maneuver if the company satisfies the agreed requirements. It replaces neither revenue nor an improvement in operating results. For shareholders, the question shifts from the size of the announced opportunity to the terms attached to using it.

What the nine-month figures actually show

The operating picture is more nuanced than the bookings headline. For the first nine months of 2026, D-Wave reported bookings of $37.4 million — a 611% jump on the prior-year period. Remaining performance obligations told a similar story of expansion: $38.3 million as of September 30, up 1,221% year over year.

Then the quarterly detail complicates the narrative. Bookings in the third quarter of 2026 fell 19% to $1.9 million. Revenue for the same quarter rose to $4.5 million, a 21% gain on the year-earlier period. The quarterly loss, meanwhile, came in higher than expected.

That divergence matters. A rising order book and rising revenue are not the same thing, and the gap between them is where the investment case now lives. The central test is conversion — turning bookings into recognized revenue, and doing so on a timeline that makes the backlog meaningful rather than merely impressive.

The cost side pushes back

Against the order momentum sits the income statement. The adjusted EBITDA loss widened 83% year over year to $37.7 million, while revenue from system sales declined by $1.5 million. Growth in the top line alone would not be sufficient reassurance if losses keep outpacing the business. Even a hefty bookings figure cannot neutralize that risk while conversion fails to deliver a more favorable result.

The bull case, then, does not rest on a single announcement. It requires a sequence: bookings becoming revenue, and the relationship between business scale and losses improving. Only then would the strong order dynamics become a convincing argument for the company's economic trajectory. In the favorable scenario, a growing share of bookings converts into revenue, giving the order growth real predictive weight — and the conditional access to CHIPS funding could add financial flexibility, provided the milestones are met. The two developments need not advance in lockstep, but investors would want both to support execution.

The sell side is trimming, not retreating

Analysts have adjusted their numbers without abandoning their positions. Jefferies analyst Kevin Garrigan cut his price target for D-Wave Quantum to $33 from $40 on Wednesday, keeping his buy rating intact. Wedbush reaffirmed its "Outperform" rating the same day, pointing to the expected system delivery to Florida Atlantic University as a potential growth driver for the fourth quarter.

The next concrete operational checkpoint is therefore the trajectory of system sales in Q4, with confirmed progress on the agreed funding milestones a secondary marker. Repeating the potential size of the financing package is not what counts — actual fulfillment of the conditions is. The decision for investors remains a wager between demonstrated order momentum and economic proof still to come. The case would firm up if D-Wave converts more booked business into revenue while improving its loss trend. Without that link, the order growth stays a potential whose commercial value has yet to show itself.